GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-08

AUTHORS

Jumpei Yoshimura, Kazuma Yamakawa, Takahiro Kinoshita, Yoshinori Ohta, Takeshi Morimoto

ABSTRACT

BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018. More... »

PAGES

614

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2

DOI

http://dx.doi.org/10.1186/s13063-018-2971-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109785241

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30409160


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gentian Violet", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Ventilator-Associated", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sample Size", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshimura", 
        "givenName": "Jumpei", 
        "id": "sg:person.0603331425.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603331425.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamakawa", 
        "givenName": "Kazuma", 
        "id": "sg:person.0662305676.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662305676.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416985.7", 
          "name": [
            "Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kinoshita", 
        "givenName": "Takahiro", 
        "id": "sg:person.015007222273.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007222273.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohta", 
        "givenName": "Yoshinori", 
        "id": "sg:person.015350567523.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350567523.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-003-1788-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043121337", 
          "https://doi.org/10.1007/s00134-003-1788-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2253-15-19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045178259", 
          "https://doi.org/10.1186/1471-2253-15-19"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13054-017-1747-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086058682", 
          "https://doi.org/10.1186/s13054-017-1747-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-08", 
    "datePublishedReg": "2018-11-08", 
    "description": "BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-018-2971-2", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7522581", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6834768", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "ventilator-associated pneumonia", 
      "initial antibiotic treatment", 
      "intensive care unit", 
      "initial antibiotic therapy", 
      "anti-pseudomonal agents", 
      "broad-spectrum antibiotics", 
      "antibiotic treatment", 
      "pneumonia trials", 
      "antibiotic choice", 
      "antibiotic therapy", 
      "Gram staining", 
      "open-label parallel-group trial", 
      "one-sided alpha level", 
      "common hospital-acquired infection", 
      "resistant Staphylococcus aureus agents", 
      "non-evaluable patients", 
      "clinical response rate", 
      "ICU-free days", 
      "ventilator-free days", 
      "parallel-group trial", 
      "guideline-based treatment", 
      "non-inferiority margin", 
      "selection of antibiotics", 
      "hospital-acquired infections", 
      "anti-MRSA agents", 
      "Medical Information Network", 
      "multidrug-resistant pathogens", 
      "primary endpoint", 
      "secondary endpoints", 
      "cause mortality", 
      "adverse events", 
      "care unit", 
      "endotracheal aspirates", 
      "ICU setting", 
      "guideline group", 
      "study protocol", 
      "patient outcomes", 
      "patients", 
      "response rate", 
      "antibiotic selection strategy", 
      "antibiotic agents", 
      "total sample size", 
      "alpha levels", 
      "trials", 
      "staining", 
      "treatment", 
      "antibiotics", 
      "therapy", 
      "endpoint", 
      "pathogenic bacteria", 
      "agents", 
      "coverage rate", 
      "rapid emergence", 
      "days", 
      "sample size", 
      "multicentre", 
      "pneumonia", 
      "group", 
      "aspirates", 
      "infection", 
      "mortality", 
      "outcomes", 
      "rate", 
      "immediate information", 
      "use", 
      "pathogens", 
      "setting", 
      "rationale", 
      "evidence", 
      "levels", 
      "protocol", 
      "spread", 
      "events", 
      "choice", 
      "bacteria", 
      "combination", 
      "margin", 
      "strategies", 
      "units", 
      "ratio", 
      "results", 
      "challenges", 
      "emergence", 
      "information", 
      "selection", 
      "size", 
      "information networks", 
      "selection strategy", 
      "network", 
      "power"
    ], 
    "name": "GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial", 
    "pagination": "614", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109785241"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2971-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30409160"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2971-2", 
      "https://app.dimensions.ai/details/publication/pub.1109785241"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_774.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-018-2971-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2971-2'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      21 PREDICATES      127 URIs      116 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2971-2 schema:about N0c433d65ecb64522a2fd7906b6532356
2 N1d6565df5f95411bafd5310f27ac7f42
3 N290216a547794dff83ee08ef7de42e54
4 N3173631eff8f49f09b3e27cab5bb0c9e
5 N41a097680bb74c8599e584a4f26c489e
6 N684e078e682d4aeda711d796495d3669
7 N691bf57c8add473db5478aff023a5bb4
8 Nbadfa5846f04492d8dca3e57baccae37
9 Ne6de91a1cb3c4efb941175f646297322
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N4c75aaff1993495db812a910f4be4794
13 schema:citation sg:pub.10.1007/s00134-003-1788-x
14 sg:pub.10.1186/1471-2253-15-19
15 sg:pub.10.1186/s13054-017-1747-5
16 schema:datePublished 2018-11-08
17 schema:datePublishedReg 2018-11-08
18 schema:description BackgroundOptimising the use of antibiotic agents is a pressing challenge to overcoming the rapid emergence and spread of multidrug-resistant pathogens in intensive care units (ICUs). Although Gram staining may possibly provide immediate information for predicting pathogenic bacteria, Gram stain-guided initial antibiotic treatment is not well established in the ICU setting. We planned the GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial to investigate whether Gram staining can safely restrict the use of broad-spectrum antibiotics in patients with ventilator-associated pneumonia (VAP), which is one of the most common hospital-acquired infections in ICUs.Methods/designThe GRACE-VAP trial is a multicentre, randomised, open-label parallel-group trial to assess the non-inferiority of Gram stain-guided initial antibiotic treatment to guidelines-based initial antibiotic treatment for the primary endpoint of clinical response rate in patients with VAP. Secondary endpoints include the coverage rates of initial antibiotic therapies, the selected rates of anti-pseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents as initial antibiotic therapies, 28-day all-cause mortality, ICU-free days, ventilator-free days and adverse events. Patients are randomly assigned to receive Gram stain-guided treatment or guidelines-based treatment at a ratio of 1:1. In the Gram stain group, results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. In the guidelines group, the combination of an anti-pseudomonal agent and an anti-MRSA agent is administered. A total sample size of 200 was estimated to provide a power of 80% with a one-sided alpha level of 2.5% and a non-inferiority margin of 20%, considering 10% non-evaluable patients.DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov, NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018.
19 schema:genre article
20 schema:isAccessibleForFree true
21 schema:isPartOf N53e23be7326644b7b186f324e317934b
22 Nc0614f94d7bc4579811e6324468f34d8
23 sg:journal.1297400
24 schema:keywords Gram staining
25 ICU setting
26 ICU-free days
27 Medical Information Network
28 adverse events
29 agents
30 alpha levels
31 anti-MRSA agents
32 anti-pseudomonal agents
33 antibiotic agents
34 antibiotic choice
35 antibiotic selection strategy
36 antibiotic therapy
37 antibiotic treatment
38 antibiotics
39 aspirates
40 bacteria
41 broad-spectrum antibiotics
42 care unit
43 cause mortality
44 challenges
45 choice
46 clinical response rate
47 combination
48 common hospital-acquired infection
49 coverage rate
50 days
51 emergence
52 endotracheal aspirates
53 endpoint
54 events
55 evidence
56 group
57 guideline group
58 guideline-based treatment
59 hospital-acquired infections
60 immediate information
61 infection
62 information
63 information networks
64 initial antibiotic therapy
65 initial antibiotic treatment
66 intensive care unit
67 levels
68 margin
69 mortality
70 multicentre
71 multidrug-resistant pathogens
72 network
73 non-evaluable patients
74 non-inferiority margin
75 one-sided alpha level
76 open-label parallel-group trial
77 outcomes
78 parallel-group trial
79 pathogenic bacteria
80 pathogens
81 patient outcomes
82 patients
83 pneumonia
84 pneumonia trials
85 power
86 primary endpoint
87 protocol
88 rapid emergence
89 rate
90 ratio
91 rationale
92 resistant Staphylococcus aureus agents
93 response rate
94 results
95 sample size
96 secondary endpoints
97 selection
98 selection of antibiotics
99 selection strategy
100 setting
101 size
102 spread
103 staining
104 strategies
105 study protocol
106 therapy
107 total sample size
108 treatment
109 trials
110 units
111 use
112 ventilator-associated pneumonia
113 ventilator-free days
114 schema:name GRam stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) trial: rationale and study protocol for a randomised controlled trial
115 schema:pagination 614
116 schema:productId N1d8894e8ab8a4bb5a325a01513ff6cbf
117 N6af06807c82544c1b823c33b9e15e12e
118 N77b08d32b20a4c1a889ac73224dee282
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785241
120 https://doi.org/10.1186/s13063-018-2971-2
121 schema:sdDatePublished 2022-12-01T06:38
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N024a90699fac4f80b7cf4ac94d344d4a
124 schema:url https://doi.org/10.1186/s13063-018-2971-2
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N024a90699fac4f80b7cf4ac94d344d4a schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N0c433d65ecb64522a2fd7906b6532356 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Randomized Controlled Trials as Topic
132 rdf:type schema:DefinedTerm
133 N1d6565df5f95411bafd5310f27ac7f42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Multicenter Studies as Topic
135 rdf:type schema:DefinedTerm
136 N1d8894e8ab8a4bb5a325a01513ff6cbf schema:name dimensions_id
137 schema:value pub.1109785241
138 rdf:type schema:PropertyValue
139 N290216a547794dff83ee08ef7de42e54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Sample Size
141 rdf:type schema:DefinedTerm
142 N2ca7b764e30042749ae26493c0d0dac2 rdf:first sg:person.011273662612.03
143 rdf:rest rdf:nil
144 N3173631eff8f49f09b3e27cab5bb0c9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Outcome Assessment, Health Care
146 rdf:type schema:DefinedTerm
147 N41a097680bb74c8599e584a4f26c489e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Pneumonia, Ventilator-Associated
149 rdf:type schema:DefinedTerm
150 N44208bf608f845a7be53b73a99c4b6d6 rdf:first sg:person.015007222273.93
151 rdf:rest Nae5f3823e9074c418bbca601db862c73
152 N4c75aaff1993495db812a910f4be4794 rdf:first sg:person.0603331425.88
153 rdf:rest Ndac0798ecd9c46d89772a1081b83dcd5
154 N53e23be7326644b7b186f324e317934b schema:issueNumber 1
155 rdf:type schema:PublicationIssue
156 N684e078e682d4aeda711d796495d3669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Data Interpretation, Statistical
158 rdf:type schema:DefinedTerm
159 N691bf57c8add473db5478aff023a5bb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Anti-Bacterial Agents
161 rdf:type schema:DefinedTerm
162 N6af06807c82544c1b823c33b9e15e12e schema:name doi
163 schema:value 10.1186/s13063-018-2971-2
164 rdf:type schema:PropertyValue
165 N77b08d32b20a4c1a889ac73224dee282 schema:name pubmed_id
166 schema:value 30409160
167 rdf:type schema:PropertyValue
168 Nae5f3823e9074c418bbca601db862c73 rdf:first sg:person.015350567523.38
169 rdf:rest N2ca7b764e30042749ae26493c0d0dac2
170 Nbadfa5846f04492d8dca3e57baccae37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Phenazines
172 rdf:type schema:DefinedTerm
173 Nc0614f94d7bc4579811e6324468f34d8 schema:volumeNumber 19
174 rdf:type schema:PublicationVolume
175 Ndac0798ecd9c46d89772a1081b83dcd5 rdf:first sg:person.0662305676.60
176 rdf:rest N44208bf608f845a7be53b73a99c4b6d6
177 Ne6de91a1cb3c4efb941175f646297322 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Gentian Violet
179 rdf:type schema:DefinedTerm
180 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
181 schema:name Medical and Health Sciences
182 rdf:type schema:DefinedTerm
183 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
184 schema:name Clinical Sciences
185 rdf:type schema:DefinedTerm
186 sg:grant.6834768 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2971-2
187 rdf:type schema:MonetaryGrant
188 sg:grant.7522581 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2971-2
189 rdf:type schema:MonetaryGrant
190 sg:journal.1297400 schema:issn 1468-6708
191 1745-6215
192 schema:name Trials
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
196 schema:familyName Morimoto
197 schema:givenName Takeshi
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
199 rdf:type schema:Person
200 sg:person.015007222273.93 schema:affiliation grid-institutes:grid.416985.7
201 schema:familyName Kinoshita
202 schema:givenName Takahiro
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015007222273.93
204 rdf:type schema:Person
205 sg:person.015350567523.38 schema:affiliation grid-institutes:grid.272264.7
206 schema:familyName Ohta
207 schema:givenName Yoshinori
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015350567523.38
209 rdf:type schema:Person
210 sg:person.0603331425.88 schema:affiliation grid-institutes:grid.416985.7
211 schema:familyName Yoshimura
212 schema:givenName Jumpei
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603331425.88
214 rdf:type schema:Person
215 sg:person.0662305676.60 schema:affiliation grid-institutes:grid.416985.7
216 schema:familyName Yamakawa
217 schema:givenName Kazuma
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662305676.60
219 rdf:type schema:Person
220 sg:pub.10.1007/s00134-003-1788-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043121337
221 https://doi.org/10.1007/s00134-003-1788-x
222 rdf:type schema:CreativeWork
223 sg:pub.10.1186/1471-2253-15-19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045178259
224 https://doi.org/10.1186/1471-2253-15-19
225 rdf:type schema:CreativeWork
226 sg:pub.10.1186/s13054-017-1747-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086058682
227 https://doi.org/10.1186/s13054-017-1747-5
228 rdf:type schema:CreativeWork
229 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
230 Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
231 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
232 Division of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, 663-8501, Nishinomiya, Hyogo, Japan
233 rdf:type schema:Organization
234 grid-institutes:grid.416985.7 schema:alternateName Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan
235 schema:name Division of Trauma and Surgical Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi, 558-8558, Osaka, Japan
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...